United States Biotechnology & Medical Research

MoonLake Immunotherapeutics (MLTX)

Track

Over the past 90 days, MoonLake Immunotherapeutics has seen 18 insider transactions, all of which were sales totaling approximately $18.38 million. Key executives, including the CEO, CFO, and Chief Scientific Officer, executed these planned and proposed sales. These transactions occurred following the company's recent earnings report, which showed an EPS miss of 6.37%.
Ticker: MLTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for MoonLake Immunotherapeutics. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 27 Jul 2026
Value US$1,190,541.94 | Price 77.17 | Shares 30,680 (+14.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-29 2026-07-27 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
30,680 +14.6%
77.17
US$1,190,542 		30,680 +14.6% 77.17 US$1,190,542
2026-07-23 2026-07-22 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
86,907 +21.3%
360.33
US$1,401,821 		86,907 +21.3% 360.33 US$1,401,821
2026-07-23 2026-07-21 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
31,373 -45.6%
56.08
US$2,509,189 		31,373 -45.6% 56.08 US$2,509,189
2026-07-21 2026-07-20 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
1,000 -1.6%
20.09
US$100,000 		1,000 -1.6% 20.09 US$100,000
2026-07-20 2026-07-15 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
1,000 -0.6%
20.01
US$100,000 		1,000 -0.6% 20.01 US$100,000
2026-07-15 2026-07-15 PrS Proposed sale
1.8
Reich Kristian

Officer

Officer
1,000
19.44
US$100,000 		1,000 19.44 US$100,000
2026-07-13 2026-07-10 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
1,000 -2.4%
20.02
US$100,000 		1,000 -2.4% 20.02 US$100,000
2026-07-13 2026-07-09 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
1,000 -1.2%
20.01
US$100,000 		1,000 -1.2% 20.01 US$100,000
2026-07-02 2026-07-01 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
47,775 -1.6%
20.03
US$956,933 		47,775 -1.6% 20.03 US$956,933
2026-06-30 2026-06-30 PrS Proposed sale
1.8
Santos da Silva Jorge

Officer; CEO

Officer
150,000
20.03
US$3,004,500 		150,000 20.03 US$3,004,500
2026-06-23 2026-06-22 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
39,120 -3.4%
22.04
US$862,205 		39,120 -3.4% 22.04 US$862,205
2026-06-18 2026-06-18 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
2,794 -0.2%
19.60
US$54,762 		2,794 -0.2% 19.60 US$54,762
2026-06-18 2026-06-17 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
15,082 -1.3%
19.68
US$296,814 		15,082 -1.3% 19.68 US$296,814
2026-06-17 2026-06-17 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
50,000 -1.7%
19.43
US$971,500 		50,000 -1.7% 19.43 US$971,500
2026-06-17 2026-06-16 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
50,000 -1.7%
18.70
US$935,000 		50,000 -1.7% 18.70 US$935,000
2026-06-17 2026-06-15 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
50,000 -1.7%
18.89
US$944,500 		50,000 -1.7% 18.89 US$944,500
2026-06-15 2026-06-15 PrS Proposed sale
1.8
Reich Kristian

Officer

Officer
150,000
19.00
US$2,850,000 		150,000 19.00 US$2,850,000
2026-05-13 2026-05-11 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
13,653 -1.2%
20.02
US$273,333 		13,653 -1.2% 20.02 US$273,333
2026-04-16 2026-04-14 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
2,426 -0.2%
19.56
US$47,453 		2,426 -0.2% 19.56 US$47,453
2026-04-14 2026-04-13 S Sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
51,873 -1.7%
18.23
US$945,645 		51,873 -1.7% 18.23 US$945,645
2026-04-14 2026-04-10 S Sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
98,127 -3.2%
18.41
US$1,806,518 		98,127 -3.2% 18.41 US$1,806,518
2026-04-10 2026-04-10 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
1,925 -0.2%
19.51
US$37,557 		1,925 -0.2% 19.51 US$37,557
2026-04-10 2026-04-10 PrS Proposed sale
1.8
Jorge Pedro Santos Radeck D Silva

CEO
150,000
18.58
US$2,787,000 		150,000 18.58 US$2,787,000
2026-04-10 2026-04-09 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
85,870 -6.7%
18.94
US$1,626,378 		85,870 -6.7% 18.94 US$1,626,378
2026-04-09 2026-04-09 PrS Proposed sale
3.2
Bodenstedt Matthias

Officer; CFO

Officer
160,870
18.46
US$2,969,660 		160,870 18.46 US$2,969,660
2026-04-02 2026-03-31 S Sale
4.1
BVF PARTNERS L P/IL
Non-Executive Director Large shareholder
248,530 -19.3%
16.79
US$4,172,819 		248,530 -19.3% 16.79 US$4,172,819
2026-04-02 2026-03-31 S Sale
4.1
BVF PARTNERS L P/IL
Non-Executive Director Large shareholder
1,569,116 -19.2%
16.79
US$26,345,458 		1,569,116 -19.2% 16.79 US$26,345,458
2026-04-02 2026-03-31 S Sale
4.1
BVF PARTNERS L P/IL
Non-Executive Director Large shareholder
1,932,354 -18.9%
16.79
US$32,444,224 		1,932,354 -18.9% 16.79 US$32,444,224
2026-03-31 2026-03-31 PrS Proposed sale
4.1
BVF PARTNERS L P/IL

10% Stockholder; Affiliate of Director

Non-Executive Director Large shareholder
3,750,000
16.93
US$63,487,500 		3,750,000 16.93 US$63,487,500
2025-12-10 2025-12-09 S Sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
70,000 -2.4%
14.49
US$1,014,300 		70,000 -2.4% 14.49 US$1,014,300
2025-12-10 2025-12-09 S Sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
72,908 -100.0%
14.43
US$1,052,062 		72,908 -100.0% 14.43 US$1,052,062
2025-12-10 2025-12-08 S Sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
130,000 -4.2%
15.08
US$1,960,400 		130,000 -4.2% 15.08 US$1,960,400
2025-12-10 2025-12-08 S Sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
130,000 -64.1%
15.08
US$1,960,400 		130,000 -64.1% 15.08 US$1,960,400
2025-12-08 2025-12-08 PrS Proposed sale
1.8
Jorge Pedro Santos Radeck Da Silva

Officer; Director; CEO

Executive Director
200,000
14.90
US$2,980,000 		200,000 14.90 US$2,980,000
2025-12-08 2025-12-08 PrS Proposed sale
1.8
Kristian Dieter Johannes Reich

Officer; Director; Chief Scientific Officer

Executive Director
202,908
14.80
US$3,003,038 		202,908 14.80 US$3,003,038
2025-10-09 2025-10-08 B Purchase
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
10,870 +1.8%
9.09
US$98,808 		10,870 +1.8% 9.09 US$98,808
2025-10-01 2025-09-30 S Sale
2.2
Chen Bihua

Former 10% Owner
5,827 -0.3%
6.96
US$40,556 		5,827 -0.3% 6.96 US$40,556
2025-10-01 2025-09-29 S Sale
2.2
Chen Bihua

Former 10% Owner
2,800,000 -58.3%
6.61
US$18,508,000 		2,800,000 -58.3% 6.61 US$18,508,000
2025-10-01 2025-09-29 S Sale
2.2
Chen Bihua

Former 10% Owner
3,390,943 -41.4%
7.58
US$25,703,348 		3,390,943 -41.4% 7.58 US$25,703,348
2025-10-01 2025-09-29 S Sale
2.2
Chen Bihua

Former 10% Owner
232,460 -2.8%
8.40
US$1,952,664 		232,460 -2.8% 8.40 US$1,952,664
2025-10-01 2025-09-29 S Sale
2.2
Chen Bihua

Former 10% Owner
70,748 -0.8%
9.38
US$663,616 		70,748 -0.8% 9.38 US$663,616
2025-07-07 2025-07-03 S Sale
3.6
Moukheibir Catherine
Non-Executive Director
23,500 -100.0%
48.79
US$1,146,565 		23,500 -100.0% 48.79 US$1,146,565
2025-07-03 2025-07-03 PrS Proposed sale
3.6
Moukheibir Catherine

Director

Non-Executive Director
23,500
48.79
US$1,146,595 		23,500 48.79 US$1,146,595
2024-10-08 2024-10-04 S Sale
4.1
BVF PARTNERS L P/IL
Non-Executive Director Large shareholder
132,549 -9.3%
50.00
US$6,627,662 		132,549 -9.3% 50.00 US$6,627,662
2024-10-08 2024-10-04 S Sale
4.1
BVF PARTNERS L P/IL
Non-Executive Director Large shareholder
836,862 -9.3%
50.00
US$41,844,439 		836,862 -9.3% 50.00 US$41,844,439
2024-10-08 2024-10-04 S Sale
4.1
BVF PARTNERS L P/IL
Non-Executive Director Large shareholder
1,030,589 -9.1%
50.00
US$51,531,099 		1,030,589 -9.1% 50.00 US$51,531,099
2024-10-08 2024-10-04 S Sale
2.9
Sturge Simon
Non-Executive Director
171,000 -49.9%
53.72
US$9,186,120 		171,000 -49.9% 53.72 US$9,186,120
2024-02-29 2024-02-29 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
4,740 -0.2%
55.89
US$264,919 		4,740 -0.2% 55.89 US$264,919
2024-02-29 2024-02-28 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
28,090 -40.1%
55.00
US$1,544,950 		28,090 -40.1% 55.00 US$1,544,950
2024-02-29 2024-02-28 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
31,910 -1.1%
55.00
US$1,755,050 		31,910 -1.1% 55.00 US$1,755,050
2024-02-29 2024-02-28 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
56,065 -1.8%
55.00
US$3,083,575 		56,065 -1.8% 55.00 US$3,083,575
2024-02-29 2024-02-27 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
29,431 -29.6%
55.00
US$1,618,705 		29,431 -29.6% 55.00 US$1,618,705
2024-02-29 2024-02-27 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
29,491 -1.0%
55.00
US$1,622,005 		29,491 -1.0% 55.00 US$1,622,005
2024-02-29 2024-02-27 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
62,810 -2.0%
55.00
US$3,454,550 		62,810 -2.0% 55.00 US$3,454,550
2024-02-23 2024-02-21 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
1,125 -0.0%
55.27
US$62,179 		1,125 -0.0% 55.27 US$62,179
2024-02-22 2024-02-21 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
569 -0.6%
55.30
US$31,466 		569 -0.6% 55.30 US$31,466
2024-02-22 2024-02-21 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
509 -0.0%
55.31
US$28,153 		509 -0.0% 55.31 US$28,153
2024-02-22 2024-02-20 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -9.1%
57.43
US$574,300 		10,000 -9.1% 57.43 US$574,300
2024-02-22 2024-02-20 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -0.3%
57.45
US$574,500 		10,000 -0.3% 57.45 US$574,500
2024-02-20 2024-02-20 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
20,000 -0.6%
57.44
US$1,148,800 		20,000 -0.6% 57.44 US$1,148,800
2024-02-20 2024-02-16 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
20,000 -0.6%
60.15
US$1,203,000 		20,000 -0.6% 60.15 US$1,203,000
2024-02-16 2024-02-16 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -8.3%
60.15
US$601,500 		10,000 -8.3% 60.15 US$601,500
2024-02-16 2024-02-16 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -0.3%
60.15
US$601,500 		10,000 -0.3% 60.15 US$601,500
2024-02-20 2024-02-15 PlS Planned sale
1.8
Santos da Silva Jorge

Chief Executive Officer

Executive Director
20,000 -0.6%
60.18
US$1,203,600 		20,000 -0.6% 60.18 US$1,203,600
2024-02-16 2024-02-15 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -7.7%
60.16
US$601,600 		10,000 -7.7% 60.16 US$601,600
2024-02-16 2024-02-15 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -0.3%
60.17
US$601,700 		10,000 -0.3% 60.17 US$601,700
2024-02-15 2024-02-15 PrS Proposed sale
1.8
Santos da Silva Jorge

CEO
200,000
63.95
US$12,790,000 		200,000 63.95 US$12,790,000
2024-02-16 2024-02-14 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -7.1%
62.43
US$624,300 		10,000 -7.1% 62.43 US$624,300
2024-02-16 2024-02-14 PlS Planned sale
1.8
Reich Kristian

Chief Scientific Officer

Officer
10,000 -0.3%
62.42
US$624,200 		10,000 -0.3% 62.42 US$624,200
2024-02-14 2024-02-14 PrS Proposed sale
1.8
Reich Kristian

Officer; CSO

Officer
200,000
63.01
US$12,602,000 		200,000 63.01 US$12,602,000
2023-12-21 2023-12-20 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
5,264 -1.0%
58.34
US$307,102 		5,264 -1.0% 58.34 US$307,102
2023-12-20 2023-12-20 PrS Proposed sale
3.2
Bodenstedt Matthias

Officer; CFO

Officer
5,264
59.27
US$311,997 		5,264 59.27 US$311,997
2023-12-21 2023-12-19 PlS Planned sale
3.2
Bodenstedt Matthias

Chief Financial Officer

Officer
94,736 -15.3%
59.22
US$5,610,266 		94,736 -15.3% 59.22 US$5,610,266
2023-12-19 2023-12-19 PrS Proposed sale
3.2
Bodenstedt Matthias

Officer; CFO

Officer
94,736
59.22
US$5,610,266 		94,736 59.22 US$5,610,266
2023-10-10 2023-10-05 B Purchase
2.2
Chen Bihua
Large shareholder
58,839 +0.7%
59.90
US$3,524,297 		58,839 +0.7% 59.90 US$3,524,297
Explore more

More insider trading research around MoonLake Immunotherapeutics

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America